Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
samalizumab (1 trial)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Multiple Myeloma (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Trials (1 total)
Trial APIs (1 total)